德国癌症研究中心DKFZ是德国最大的医学健康研究中心，人数约近3000人。该机构曾经与国内的复旦大学、同济医学大学、第四军医大学等单位有诸多的人员交流和协作。但只是近几年才，因为DKFZ开始重视在全球的Alumni的联谊工作，才开始收集整理过去曾在DKFZ进修深造或获得学位的回国的前学友Alumni。 但是由于年长日久，许多联系丢失，目前仅仅只能掌握到45人如下，还希望有热心人进一步提供 准确 信息。 Surname First Name Title Institute Street Town E-mail 1' Bai Hsing Chen Dr. Lane 2, Wu Kai Sha Village, Ma On Shan Hongkong alfa_bai@hotmail.com 2' Bian Huijie Prof. Dr. Fourth Military Medical University Department of Cell Biology Cell Engineering Research Center Changle West Road 17 Xi'an huijiebian@hotmail.com 3' Chen Libo Dr. 6th People' hospital of Shanghai Shanghai 4' Chen Hao Prof. Dr. Medical School, Zhejiang University Hangzhou kehao@mail.hz.zj.cn 5' Cao Yi Prof. Dr. Inst. Zoology, CAS Kunming caoy@mail.kiz.ac.cn 6' Chen Sheng Dr. Tongji Medical College Union Hospital, Tumor Center Wu Jia Dun 156 Hankou, Wuhan Shengchen086@yahoo.com.cn 7' CHEN Zu-Wang Dr. 189 Yu-Quing Rd. Apt. 504 Shanghai 8' D i Cuixia Prof. Dr Inst. Modern Physics, CAS Lanzhou dicx@impcas.ac.cn 9' Dan Zili Dr.med. Institution of Chinese Medicine Gastroenterology 1095 Jiefang Avenue Wuhan danzili@msn.com 10' Fang Zhizheng Prof.Dr. Wuhan Inst. of Biolog. Products Director of R D Dept. 9 Linjiang Road, Wuchang Wuhan zhizfang@yahoo.com.cn 11' Jiang Shiming Dr. Shandong University Dept. of Biology Jinan 12' LEI Haixing Dr. Dalian Medical University Dalian haixinlei@dlmedu.edu.cn 13' Li Jie Instittute of Cancer, Chinese Academy of Medical Sciences Beijing 14' LI Mingfa Prof. Dr. Shanghai Jiaotong University Shanghai mfli@sjtu.edu.cn 15' Li Ming-Song Dr. Nanfang Hospital Dept. of Gastroenterology Guangzhou 16' Li Zhen Prof. Dr. Fourth Medical Military University Histology and Embryology Chang Le West Road 17 Xi'an lizhenhe@fmmu.edu.cn 17' Li Zheng Dr. Northwest University - College of Life Sciences Laboratory for Glycomics 12th floor, Science Building Xi'an zhengli@nwu.edu.cn 18' Liao Yongde Dr. Tongji Hospital Dept. of Surgery Jiefang Dadao 1095 Wuhan ydliao@tjh.tjmu.edu.cn 19' Lin Jiang Dr. Zhongshan Hospital Medica School of Fudan University Shanghai linjiang@zshospital.net 20' Lin Yuchun Dr. Cancer Inst., Chinese Academy of Med. Sci. Department of Virology Zuoanmenwai Beijing 21' Liu Pei-Li Prof. Shanghai Medical University 138 Yi Xue Yuan Road Shanghai 22' Mao Bingyu Dr. Chinese Academy of Sciences - Kunming Institute of Zoology State Key Laboratory of Genetic Resources and Evolution 32 Jiaochang East Road Kunming mao@mail.kiz.ac.cn 23' Mi Huaifeng Prof. Dr. Nankai Univ. Chemical College Inst. of Polymer Chemistry Nankai Univ. Tianjin hfmi@nankai.edu.cn 24' Niu Yun Prof. Dr. Tianjin Med. University, Tumor Institute and Hospital Breast Pathology Lab Huan-Hu-Xi Road Ti Yuan Bei Tianjin yunniu2000@yahoo.com.cn 25' Peng Yao Dr. pyao1@sohu.com 26' Qi Jian-de Xi'an Medical College Library Xi'an Shaanxi 27' Ran Zhi Hua Dr. Shanghai Ren-Ji Hospital, Shanghai Institute of Digestive Disease Dept. of Gastroenterology 145 Shan-Dong Zhong Road Shanghai z-ran@online.sh.cn 28' Ruan Youbing . Tongji Med. Univ. Ultrastructural Pathology 13 Hang Kong Road Wuhan 29' Ruan Yubing Prof. Dr. Tong Ji Medical College Pathology Hong kong Road Wuhan Ruanyb@public.wh.hb.cn 30' Su Qin Prof. Dr. Tissue Biomarker and Explorative Pathology Labs Shanghai Roche Translational Research Sciences (TRS) and pRED China Lane 917, No. 6, Halei Road, Pudong Shanghai qinsu@ymail.com 31' Tao Wie Dr. Peking University Cell Biology Beijing weitao@pku.edu.cn 32' Wang Junsong Prof. Dr. China Pharmaceutical University State Key Laboratory of Natural Medicines wang.junsong@gmail.com 33' Wang Minsheng Dr. The first Milit. Med. Univ. Nantan Hosp. Dept. of Orthopaedics and Traumat. Guangzhou 34' Wang Minsheng Dr. Director, Jiangsu Provincial Centre for Disease Prevention and Control Jiangsu 173, Nanjing 35' Wang Lu Center for Theoretical Biology Physics Department Yi He Yuan Lu 95 Beijing wanglu624@hotmail.com 36' Wang Rukuang Prof. Chinese Inst. of Med. Information Chinese Academy of Med. Sciences 3. Yabao Road Beijing wangrk@ms.imicams.ac.cn 37' Wang Shumei Tangdu Hospital, Fourth Military Med. University Department of Pathology No. 1 Xinsi Road, Baqiao District Xi'an Wangshumei1979@msn.com 38' Wang Ying Dr. Nanjing Medical University Center of Metabolic Disease Research Hanzhong Road, 140, Gulou Nanjing wangying_yc@hotmail.com 39' Wang Ziling Dr. Beijing Institute of Transfusion Medicine Dept. Immunohematology Taiping Road 27 Beijing wangzl_mm@yahoo.com.cn 40' Wu da-gang Prof. Dr. The Academy of Sciences of China Institute of Botany Kunming Yunnan wdgykp@163.com 41' Wu Hua Prof. Dr. Xiamen Frist Hospital Dept. of Nuclear Medicine Zhenhai road 55 Xiamen hyx@tjh.tjmu.edu.cn 42' Wu W e i Prof. Dr. Tsunghua University - School of Life Sciences Dept. of Biological Sciences and Biotechnology Beijing wwu@mail.tsinghua.edu.cn 43' Xiong Yufang Dr. Tang ji Med. Univ. Biochemistry and Molecular Biology Hongkong Road 13 Wuhan, Hubei 44' Xu Xiaojun China Pharmaceutical University State Key Laboratory of Natural Medicines Nanjing Xiaojunxu2000@googlemail.com 45' Yan Hua Dr. Wuhan Inst. of Biological Products 9 Linjiang Road Wuchang Wuhan 46' Yin Qian Dr. Inst. Tongji Hospital of Tongji Med. University Dept. of General Surgery, Tongji hospital Street Jiefang Avenue 13 Wuhan jejorin@hotmail.com 47' Yu Y.Q. Dr. Med. Centre of Fudan Univ., Liver Cancer Inst., Uhongshan Hospital Dept. of Hepatic Oncology Shanghai 48' Zeng Jinyang Dr. Tonji Med. Univ. Dept. Immunol. Wuhan 49' Zhang Chunfu Dr. Shanghai Jiaotong University huashalu 1954 Shanghai zchunfu@yahoo.com.cn/cfzhang@sjtu.edu.cn 50' Zhang Wei Prof.Dr. Tangdu Hospital Fourth Military Med. University Xi'an, Shaanxi zhwlyh@fmmu.edu.cn 51' Zhou Shixin Dr. Peking University Health Science Center Stem Cell Research Center Xueyuan Road 38 - Haidian District Beijing zsx@bjmu.edu.cn 52' Zhou Xin-Da Prof. Zhongshan Hospital Liver Cancer Institute 136 Yi Xue Yuan Road Shanghai 53' Zhou Youshang Prof. Wuhan Medizinische Hochschule Institut für hygienische Statistik Wuhan, Hubei 54' Zhou Wei Prof. Dr. Shaoyifu Hospital, Medical School of Zhejiang University
德国海德堡与匈牙利布达佩斯10月12日消息：作为免疫治疗技术先行者的Genetic Immunity公司（OTCBB：PWRV）与海德堡德国癌症研究中心签订了一项联合开发基于DNA技术治疗人类乳头状瘤病毒（HPV）感染疫苗的协议。该病毒会引起的子宫颈癌及肛门，阴茎，外阴，阴道和口咽等部位的癌症。目前的HPV疫苗（Cervarix和Gardasil）只有对病毒自身的预防功能，而不具有人乳头瘤病毒HPV引发疾病的治疗效果。 由Lutz.Gissmann教授的领导DKFZ基因组修饰和癌变过程团队，将开展一个临床前研究项目，用遗传免疫的纳米医学配方和朗格汉斯细胞定位管理技术评估DKFZ的HPV-特定DNA质粒的疗效。 DKFZ是肿瘤病毒学的世界领先科研单位，哈拉尔德·楚尔·豪森正是因为对人乳头状瘤病毒引发的子宫颈癌的研究被授予诺贝尔医学奖。曾为德国癌症研究中心前科学主任的楚尔·豪森率行发现子宫颈癌是因病毒感染而引起。由他的研究成果诞生的疫苗可防止最常见女性癌症之一种。楚尔·豪森与发现导致艾滋病HIV病毒的弗朗索瓦丝•巴尔 - 西诺西和吕克·蒙塔尼分享了当年的诺贝尔医学奖。 “这种癌症新的疫苗将有巨大的市场价值，因为过去所开发的疫苗在用于治疗由人乳头瘤病毒引起的症状时并不具有防癌的功能。我们现在想对那些已经因为性爱可能遭受HPV感染的人群也能提供防护。“ 遗传免疫公司CEOJulianna Lisziewicz博士说。 10/12/12 - DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine HEIDELBERG, GERMANY and BUDAPEST, HUNGARY (Marketwire) 10/12/12 Genetic Immunity (OTCBB: PWRV), a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on HPV-related diseases, so they will not treat existing diseases or conditions caused by HPV. The Division of Genome Modifications and Carcinogenesis led by Prof. Dr. Lutz Gissmann will initiate a preclinical research program to evaluate the therapeutic efficacy of the DKFZ's HPV-specific plasmid DNA using Genetic Immunity's nanomedicine formulation and Langerhans cell-targeting administration technologies. DKFZ is a world leading research center in tumor virology. Harald zur Hausen was awarded the Nobel Medicine Prize for his work on HPV-caused cancer of the cervix. Zur Hausen, former Scientific Director of the German Cancer Research Center, is recognized for finding that cervical cancer is caused by viral infections. His research made it possible to develop a vaccine against one of the most frequent cancers in women. Zur Hausen shared the Nobel Prize for Medicine with Françoise Barré-Sinoussi and Luc Montagnier for discovering HIV, the virus that causes AIDS. "There is a huge unmet medical need for such cancer vaccine, because vaccines we have developed earlier do not provide protection against cancer when used for treatment of existing conditions caused by HPV. Our goal is to provide protection against cancer for patients after the onset of sexual activity, after they might be exposed to HPV," said Dr. Julianna Lisziewicz, CEO of Genetic Immunity. Genetic Immunity has successfully tested in clinical trials DermaVir, a candidate immunotherapy for the cure of HIV. This new collaboration is using the clinically proven technology expanding the pipeline to another deadly viral disease that causes cancer. The partners will test whether HPV-specific memory T cells induced by Genetic Immunity's nanomedicine products could protect against cancer after infection has occurred. "We found that Genetic Immunity technology is unique to target the vaccine DNA into the nucleus of the Langerhans cells. We believe that it will provide a breakthrough in cancer immunotherapy. We pioneered HPV prophylactic vaccines with new innovations and we would like to expand this tradition to therapeutic setting," said Dr. Prof. Gissmann of DKFZ. Genetic Immunity is a wholly owned subsidiary of Power of the Dream Ventures, Inc. (OTCBB: PWRV). About Genetic Immunity Genetic Immunity, part of Power of the Dream Ventures, Inc. (PWRV), is a clinical stage technology company committed to discovering, developing, manufacturing and commercializing a new class of immunotherapeutic biologic drugs for the treatment of viral infections, cancer and allergies. Our Langerhans cell-targeting nanomedicines are exceptional in both safety and immune modulating activity boosting specific Th1-type central memory T cells. These are essential to eliminate infected cells or cancerous cells, and balance the immune reactivity in response to allergens. In 1988 Drs. Lisziewicz and Lori founded Genetic Immunity in the US after they described the 1st patient whose immune system was boosted to control HIV after treatment interruption (Lisziewicz et al. New England Journal of Medicine 1999) that lead to the invention of DermaVir. The Company's innovative technology team directed by Dr. Lisziewicz, a champion of immune boosting therapies, is now headquartered in Budapest, Hungary. She has been invited into the Scientific Advisory Board of the HIV Cure Initiative led by Francoise Barre-Sinoussi Nobel Prize Laureate for her HIV research in 2009. For more information please visit http://www.geneticimmunity.com About DKFZ The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg where promising approaches from cancer research are translated into the clinic. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. The center is a member of the Helmholtz Association of National Research Centers. Ninety percent of its funding comes from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg. Add to Digg Bookmark with del.icio.us Add to Newsvine Contact: Dr. Zsolt Lisziewicz Chief Operating Officer Genetic Immunity Phone: +36-1-272-0364 Cell: +36-30-211-6402 Email: Email Contact
标签: DKFZ
